HK1180237A1 - Antimicrobial peptide, compositions, and methods of use - Google Patents

Antimicrobial peptide, compositions, and methods of use

Info

Publication number: HK1180237A1
Authority: HK; Hong Kong
Prior art keywords: compositions; methods; antimicrobial peptide; antimicrobial; peptide
Prior art date: 2007-07-26

Application number

HK13107613.7A

Other languages

Chinese (zh)

Inventor

．斯通

．沃

Original Assignee

雷文斯治療公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-26

Filing date

2013-06-28

Publication date

2013-10-18

2013-06-28 Application filed by 雷文斯治療公司 filed Critical 雷文斯治療公司

2013-10-18 Publication of HK1180237A1 publication Critical patent/HK1180237A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Dermatology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Zoology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Birds (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Ophthalmology & Optometry (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Cosmetics (AREA)

HK13107613.7A 2007-07-26 2013-06-28 Antimicrobial peptide, compositions, and methods of use HK1180237A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US95205907P	2007-07-26	2007-07-26

Publications (1)

Publication Number	Publication Date
HK1180237A1 true HK1180237A1 (en)	2013-10-18

Family

ID=40281862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK13107613.7A HK1180237A1 (en)	2007-07-26	2013-06-28	Antimicrobial peptide, compositions, and methods of use

Country Status (25)

Country	Link
US (1)	US8623811B2 (en)
EP (3)	EP3120862B1 (en)
JP (5)	JP5401457B2 (en)
KR (4)	KR101717275B1 (en)
CN (2)	CN101842107B (en)
AU (1)	AU2008278593B2 (en)
BR (3)	BR122019000266B1 (en)
CA (1)	CA2694046C (en)
CO (1)	CO6260098A2 (en)
CR (1)	CR11239A (en)
CY (2)	CY1118503T1 (en)
DK (2)	DK2178549T3 (en)
ES (2)	ES2805225T3 (en)
HK (1)	HK1180237A1 (en)
HR (1)	HRP20161722T1 (en)
HU (1)	HUE031136T2 (en)
IL (3)	IL203173A (en)
LT (1)	LT2178549T (en)
MX (1)	MX2010000916A (en)
NZ (1)	NZ582459A (en)
PL (1)	PL2178549T3 (en)
PT (2)	PT2178549T (en)
SG (1)	SG188128A1 (en)
SI (1)	SI2178549T1 (en)
WO (1)	WO2009015385A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080226551A1 (en) *	2006-12-29	2008-09-18	Revance Therapeutics, Inc.	Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
CN101842107B (en) *	2007-07-26	2014-04-23	雷文斯治疗公司	Antimicrobial peptide, compositions , and methods of use
US8080518B2 (en) *	2007-12-05	2011-12-20	Arbor Vita Corporation	Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2271670T3 (en)	2008-03-14	2015-05-29	Allergan Inc	Immuno-based botulinum toxin serotype a activity assays
AU2009332947C1 (en) *	2008-12-31	2019-01-03	Revance Therapeutics, Inc.	Injectable botulinum toxin formulations
EP2413947B1 (en) *	2009-04-01	2020-04-29	Revance Therapeutics, Inc.	Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
EP2440231B1 (en)	2009-06-10	2019-12-04	NoNO Inc.	Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
EP2445521A4 (en) *	2009-06-25	2015-08-26	Revance Therapeutics Inc	Albumin-free botulinum toxin formulations
US8387798B1 (en)	2012-04-27	2013-03-05	Abdulmohsen E. A. H. Al-Terki	Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en)	2011-06-02	2018-07-17	Abdulmohsen E. A. H. Al-Terki	Multiple oral and nasal surgical procedures method and kit
FR2997304B1 (en)	2012-10-26	2017-07-07	Isp Investments Inc	USE OF FLAX EXTRACT AS AN ACTIVATOR ACTIVE AGENT OF THE SYNTHESIS OF ANTIMICROBIAL PEPTIDES
WO2014066916A2 (en)	2012-10-28	2014-05-01	Revance Therapeutics, Inc.	Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) *	2013-02-28	2014-08-28	Dt Scimed, Llc	Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11793783B2 (en)	2015-08-05	2023-10-24	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US11684567B2 (en)	2015-08-05	2023-06-27	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US11446236B2 (en)	2015-08-05	2022-09-20	Cmpd Licensing, Llc	Topical antimicrobial compositions and methods of formulating the same
KR20180052754A (en)	2015-09-17	2018-05-18	콘트라펙트 코포레이션	Use of lysine to restore / enhance antimicrobial activity of antibiotics inhibited in the presence of pulmonary surfactant
US10105381B2 (en) *	2016-05-23	2018-10-23	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US10144767B2 (en) *	2016-08-18	2018-12-04	Board Of Regents Of The University Of Nebraska	Anti-microbial peptides and coatings
CN117731591A (en) *	2016-11-21	2024-03-22	艾里奥治疗公司	Transdermal delivery of large agents
US20210162026A1 (en)	2017-08-28	2021-06-03	Revance Therapeutics, Inc.	Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CN107353334B (en) *	2017-08-30	2020-02-07	四川大学	Bionic anticarious polypeptide based on casein-rich saliva, derivatives and salts thereof and application
CN107556374B (en) *	2017-08-30	2020-02-07	四川大学	Saliva prolin-rich bionic anticarious functional polypeptide, derivative and salt thereof and application thereof
JP7266202B2 (en) *	2018-02-19	2023-04-28	株式会社ファンケル	Cosmetics and anti-inflammatory agents

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744166A (en) *	1989-02-25	1998-04-28	Danbiosyst Uk Limited	Drug delivery compositions
US5804604A (en) *	1989-12-21	1998-09-08	Biogen, Inc.	Tat-derived transport polypeptides and fusion proteins
US5747641A (en) *	1989-12-21	1998-05-05	Biogen Inc	Tat-derived transport polypeptide conjugates
WO1993021941A1 (en) *	1992-04-23	1993-11-11	Allelix Biopharmaceuticals Inc.	Treatment of herpesvirus infection
ES2123062T3 (en)	1992-08-21	1999-01-01	Biogen Inc	TRANSPORTATION POLYPEPTIDES DERIVED FROM TAT PROTEIN.
AU685862B2 (en) *	1993-10-22	1998-01-29	Allelix Biopharmaceuticals Inc.	Treatment of cytomegalovirus infection
ES2207910T5 (en)	1993-12-28	2010-05-21	Allergan, Inc.	BOTULINIC TOXINS TO MODULATE SECRETIONS CONTROLLED BY THE COLINERGIC SYSTEM.
US6232295B1 (en)	1994-10-12	2001-05-15	Jon Faiz Kayyem	Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) *	1995-04-21	1995-06-07	Speywood Lab Ltd	A novel agent able to modify peripheral afferent function
EP0846128B1 (en) *	1995-08-23	2008-10-29	University Of British Columbia	Antimicrobial cationic peptides and methods of screening for the same
US6043218A (en) *	1996-10-22	2000-03-28	Medical University Of South Carolina	Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en)	1996-11-06	1997-01-08	Schacht Etienne H	Delivery of DNA to target cells in biological systems
EP1037911A4 (en) *	1997-12-10	2003-07-23	Univ Washington	Anti-pathogen system and methods of use thereof
WO1999031261A1 (en) *	1997-12-12	1999-06-24	Onyx Pharmaceuticals, Inc.	SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS
BR9914891A (en)	1998-10-27	2001-07-17	Mayo Foundation	Wound healing improvement processes
EP1137664A2 (en)	1998-12-10	2001-10-04	Washington University	Protein transduction system and methods of use thereof
DE69825495T2 (en)	1998-12-23	2005-07-28	Idea Ag	IMPROVED FORMULATION FOR TOPICAL, NON-INVASIVE APPLICATION IN VIVO
US7056656B1 (en) *	1999-01-25	2006-06-06	University Of Medicine And Dentistry Of New Jersey	Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) *	1999-06-09	2003-12-25	Wolff Jon A.	Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) *	1999-07-21	2006-03-07	Amgen, Inc.	VGF fusion polypeptides
US6669951B2 (en)	1999-08-24	2003-12-30	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) *	1999-09-13	2003-04-08	Keraplast Technologies, Ltd.	Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) *	1999-11-12	2005-01-18	Massachusetts Institute Of Technology	Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US6670322B2 (en) *	2000-06-01	2003-12-30	Wisconsin Alumni Research Foundation	Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) *	2000-07-21	2004-11-04	Essentia Biosystems, Inc.	Multi-component biological transport systems
ES2617692T3 (en) *	2000-07-21	2017-06-19	Revance Therapeutics, Inc.	Multi-component biological agent transport systems
US20030215412A1 (en) *	2000-07-21	2003-11-20	Essentia Biosystems, Inc.	Induction of hair growth with vascular endothelial growth factor
US6696038B1 (en) *	2000-09-14	2004-02-24	Expression Genetics, Inc.	Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) *	2000-11-17	2002-09-12	Allergen Sales, Inc.	Modified clostridial neurotoxins with altered biological persistence
DE60233137D1 (en)	2001-02-16	2009-09-10	Univ R	TRANSPORTER WITH FILLED ARGININE PARTICLES
WO2002090520A2 (en) *	2001-05-09	2002-11-14	Yale University	Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) *	2001-11-28	2006-06-13	Genta Salus Llc	Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CA2469336C (en) *	2001-12-11	2013-06-11	The Board Of Trustees Of The Leland Stanford Junior University	Guanidinium transport reagents and conjugates
AU2003216389A1 (en)	2002-02-21	2003-09-09	Essentia Biosystems, Inc.	Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) *	2002-05-14	2003-11-20	Lei Yu	Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en)	2002-07-11	2004-01-15	Allergan, Inc.	Transdermal botulinum toxin compositions
JP4154218B2 (en) *	2002-11-27	2008-09-24	寛紀高麗	Novel antibacterial polypeptides and their use
IL153557A0 (en) *	2002-12-19	2003-07-06	Yitzchak Hillman	Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
MXPA05006359A (en) *	2002-12-19	2006-02-08	Yitzchak Hillman	Disease treatment via antimicrobial peptide inhibitors.
EP1594969B1 (en) *	2003-02-01	2015-05-20	Janssen Sciences Ireland UC	Active immunization to generate antibodies to soluble a-beta
US7482016B2 (en) *	2003-03-19	2009-01-27	The J. David Gladstone Institutes	Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
US7125842B2 (en) *	2003-04-07	2006-10-24	Canbas Co. Ltd.	Anti-fungal compounds and methods of use
CN1901933A (en) *	2003-09-12	2007-01-24	英属哥伦比亚大学	Methods of stimulating innate immunity using cationic peptides
JP2005120050A (en) *	2003-10-20	2005-05-12	Toagosei Co Ltd	New antimicrobial peptide and its utilization
US8092788B2 (en) *	2004-03-03	2012-01-10	Revance Therapeutics, Inc.	Compositions and methods for topical diagnostic and therapeutic transport
ES2554821T3 (en)	2004-03-03	2015-12-23	Revance Therapeutics, Inc.	Topical application and transdermal release of botulinum toxins
CN103360485A (en) *	2004-08-18	2013-10-23	诺瓦生命科学有限公司	Antimicrobial peptides comprising an arginine-and/or lysine-containing motif
EP1656951A1 (en) *	2004-11-12	2006-05-17	Xigen S.A.	Conjugates with enhanced cell uptake activity
US20080207522A1 (en)	2004-11-12	2008-08-28	Hancock Robert E W	Antimicrobial Peptides
EP1661912A1 (en)	2004-11-29	2006-05-31	Xigen S.A.	Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (en) *	2004-12-06	2011-07-20	東亞合成株式会社	Antibacterial peptides and their use
JP2006238751A (en) *	2005-03-02	2006-09-14	Toagosei Co Ltd	Antibacterial peptide having verotoxin combining ability and utilization of the same
RU2007136616A (en)	2005-03-03	2009-04-10	Риванс Терапьютикс, Инк. (Us)	COMPOSITION AND METHOD FOR LOCAL USE AND PERFORMANCE OF BOTULIN TOXIN
US8022179B2 (en)	2005-03-03	2011-09-20	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of an oligopeptide
KR20080006568A (en)	2005-03-30	2008-01-16	레반스 테라퓨틱스, 아이엔씨.	Compositions and methods for treating acne
CN101355962A (en)	2005-11-17	2009-01-28	雷文斯治疗公司	Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2008082889A2 (en)	2006-12-29	2008-07-10	Revance Therapeutics, Inc.	Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
US20080226551A1 (en)	2006-12-29	2008-09-18	Revance Therapeutics, Inc.	Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
CN101842107B (en) *	2007-07-26	2014-04-23	雷文斯治疗公司	Antimicrobial peptide, compositions , and methods of use
AU2009332947C1 (en)	2008-12-31	2019-01-03	Revance Therapeutics, Inc.	Injectable botulinum toxin formulations

2008
- 2008-07-28 CN CN200880100641.7A patent/CN101842107B/en active Active
- 2008-07-28 MX MX2010000916A patent/MX2010000916A/en active IP Right Grant
- 2008-07-28 ES ES16184094T patent/ES2805225T3/en active Active
- 2008-07-28 KR KR1020157019647A patent/KR101717275B1/en active IP Right Grant
- 2008-07-28 NZ NZ582459A patent/NZ582459A/en unknown
- 2008-07-28 CA CA2694046A patent/CA2694046C/en active Active
- 2008-07-28 KR KR1020177002763A patent/KR20170016031A/en not_active Application Discontinuation
- 2008-07-28 SI SI200831732T patent/SI2178549T1/en unknown
- 2008-07-28 PT PT88266085T patent/PT2178549T/en unknown
- 2008-07-28 EP EP16184094.7A patent/EP3120862B1/en active Active
- 2008-07-28 BR BR122019000266-5A patent/BR122019000266B1/en active IP Right Grant
- 2008-07-28 HU HUE08826608A patent/HUE031136T2/en unknown
- 2008-07-28 ES ES08826608.5T patent/ES2609914T3/en active Active
- 2008-07-28 EP EP08826608.5A patent/EP2178549B1/en active Active
- 2008-07-28 AU AU2008278593A patent/AU2008278593B2/en active Active
- 2008-07-28 US US12/669,705 patent/US8623811B2/en active Active
- 2008-07-28 PL PL08826608T patent/PL2178549T3/en unknown
- 2008-07-28 DK DK08826608.5T patent/DK2178549T3/en active
- 2008-07-28 LT LTEP08826608.5T patent/LT2178549T/en unknown
- 2008-07-28 KR KR1020107003133A patent/KR101722038B1/en active IP Right Grant
- 2008-07-28 PT PT161840947T patent/PT3120862T/en unknown
- 2008-07-28 JP JP2010518431A patent/JP5401457B2/en not_active Expired - Fee Related
- 2008-07-28 EP EP20166266.5A patent/EP3741380A1/en active Pending
- 2008-07-28 WO PCT/US2008/071350 patent/WO2009015385A1/en active Application Filing
- 2008-07-28 CN CN201210375756.5A patent/CN102872447B/en active Active
- 2008-07-28 KR KR1020187007958A patent/KR102088949B1/en active IP Right Grant
- 2008-07-28 BR BR122019000258-4A patent/BR122019000258B1/en active IP Right Grant
- 2008-07-28 BR BRPI0813627-0A patent/BRPI0813627B1/en active IP Right Grant
- 2008-07-28 DK DK16184094.7T patent/DK3120862T3/en active
- 2008-07-28 SG SG2013009832A patent/SG188128A1/en unknown
2010
- 2010-01-06 IL IL203173A patent/IL203173A/en active IP Right Grant
- 2010-01-27 CR CR11239A patent/CR11239A/en not_active Application Discontinuation
- 2010-02-26 CO CO10023449A patent/CO6260098A2/en not_active Application Discontinuation
2012
- 2012-12-20 IL IL223784A patent/IL223784A/en active IP Right Grant
- 2012-12-20 IL IL223785A patent/IL223785A/en active IP Right Grant
2013
- 2013-06-28 HK HK13107613.7A patent/HK1180237A1/en unknown
- 2013-10-28 JP JP2013222846A patent/JP5965884B2/en not_active Expired - Fee Related
2016
- 2016-07-04 JP JP2016132290A patent/JP2017002057A/en active Pending
- 2016-12-14 HR HRP20161722TT patent/HRP20161722T1/en unknown
- 2016-12-14 CY CY20161101296T patent/CY1118503T1/en unknown
2018
- 2018-08-17 JP JP2018153719A patent/JP6722241B2/en active Active
2020
- 2020-06-19 JP JP2020105975A patent/JP2020169190A/en active Pending
- 2020-07-27 CY CY20201100692T patent/CY1123176T1/en unknown

Also Published As

Publication number	Publication date
EP2178549A1 (en)	2010-04-28
WO2009015385A1 (en)	2009-01-29
US8623811B2 (en)	2014-01-07
HRP20161722T1 (en)	2017-02-10
PT3120862T (en)	2020-06-25
CN101842107A (en)	2010-09-22
KR101722038B1 (en)	2017-04-03
CA2694046A1 (en)	2009-01-29
BR122019000258B1 (en)	2021-09-14
HUE031136T2 (en)	2017-07-28
CY1118503T1 (en)	2017-07-12
US20100215591A1 (en)	2010-08-26
JP5965884B2 (en)	2016-08-10
KR20180031824A (en)	2018-03-28
ES2805225T3 (en)	2021-02-11
KR20150090268A (en)	2015-08-05
SG188128A1 (en)	2013-03-28
NZ582459A (en)	2012-05-25
JP2019006791A (en)	2019-01-17
CO6260098A2 (en)	2011-03-22
CN102872447B (en)	2015-09-30
CN102872447A (en)	2013-01-16
JP2014076993A (en)	2014-05-01
PT2178549T (en)	2016-12-20
ES2609914T3 (en)	2017-04-25
AU2008278593B2 (en)	2015-04-09
JP2017002057A (en)	2017-01-05
JP2020169190A (en)	2020-10-15
KR20170016031A (en)	2017-02-10
DK3120862T3 (en)	2020-06-22
EP3120862B1 (en)	2020-04-29
CY1123176T1 (en)	2021-10-29
IL223784A (en)	2015-02-26
AU2008278593A2 (en)	2011-05-12
DK2178549T3 (en)	2017-01-09
LT2178549T (en)	2017-01-25
EP3120862A1 (en)	2017-01-25
KR101717275B1 (en)	2017-03-16
KR102088949B1 (en)	2020-03-13
MX2010000916A (en)	2010-06-02
CR11239A (en)	2010-06-29
AU2008278593A1 (en)	2009-01-29
IL203173A (en)	2014-12-31
SI2178549T1 (en)	2017-08-31
BRPI0813627A2 (en)	2014-12-23
CN101842107B (en)	2014-04-23
JP6722241B2 (en)	2020-07-15
BR122019000266B1 (en)	2021-09-14
JP2010534684A (en)	2010-11-11
KR20100047867A (en)	2010-05-10
CA2694046C (en)	2023-09-12
IL223785A (en)	2015-02-26
PL2178549T3 (en)	2017-03-31
EP3741380A1 (en)	2020-11-25
EP2178549A4 (en)	2014-02-19
BRPI0813627B1 (en)	2021-09-14
EP2178549B1 (en)	2016-09-14
JP5401457B2 (en)	2014-01-29

Publication	Publication Date	Title
HK1180237A1 (en)	2013-10-18	Antimicrobial peptide, compositions, and methods of use
GB2469245B (en)	2013-04-24	Antimicrobial compositions and methods of use thereof
EP2162004A4 (en)	2013-01-16	Antimicrobial compositions and uses thereof
IL209507A0 (en)	2011-01-31	Antimicrobial compositions and methods of use thereof
IL193297A0 (en)	2009-08-03	Imidazole-based compounds, compositions comprising them and methods of their use
IL230759A0 (en)	2014-03-31	Substituted acylanilide, composition comprising it and uses thereof
EP2389071A4 (en)	2012-08-08	Biofilm-removing antimicrobial compositions and uses thereof
IL204442A (en)	2015-05-31	F1f0-atpase inhibitors, pharmaceutical compositions comprising them and use thereof
EP2326171A4 (en)	2014-06-25	Antimicrobial compositions and methods of use
EP2276339A4 (en)	2012-07-18	Antimicrobial composition and use
HK1138616A1 (en)	2010-08-27	Novel laccases, compositions and methods of use
EP2217614A4 (en)	2011-12-07	Antimicrobial compositions, formulations and uses thereof
GB0706077D0 (en)	2007-05-09	Methods, Compositions and uses thereof
IL211204A0 (en)	2011-04-28	Mucoadherents compositions and their use
GB0813323D0 (en)	2008-08-27	Antimicrobial compositions and methods
GB0819432D0 (en)	2008-12-03	Compound, composition and use
EP1998753A4 (en)	2011-05-04	High-deposition compositions and uses thereof
IL213026A0 (en)	2011-07-31	TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
GB0715428D0 (en)	2007-09-19	Compositions and uses thereof
HK1151242A1 (en)	2012-01-27	Mntf peptide compositions and methods of use mntf
GB0701170D0 (en)	2007-02-28	Compositions and uses thereof
GB0701171D0 (en)	2007-02-28	Compositions and uses thereof
EP2010141A4 (en)	2011-05-04	High-deposition compositions and uses thereof
IL207174A0 (en)	2010-12-30	Peptides, compositions, and uses thereof
GB0725264D0 (en)	2008-02-06	Compositions and uses thereof